+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lymphoma Treatment Market Size, Share & Trends Analysis Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Drugs (Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda), Region, and Segment Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • October 2024
  • Region: Global
  • Grand View Research
  • ID: 6024654
Description Jump to:
The global lymphoma treatment market size is expected to reach USD 11.97 billion by 2030, registering a CAGR of 8.3% from 2025 to 2030. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.

Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.

Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.

Lymphoma Treatment Market Report Highlights

  • Non-Hodgkin Lymphoma (NHL) dominated the market with the largest revenue share of 86.2% in 2024, driven by the increasing incidence of NHL, with projections indicating a significant rise in cases over the coming years.
  • Hodgkin Lymphoma (HL) is expected to grow at a CAGR of 15.7% over the forecast period attributed to a rising number of diagnosed cases and advancements in diagnostic technologies that facilitate earlier detection.
  • Rituxan (MabThera) dominated the market and accounted for the largest revenue share of 28.8% in 2024, attributed to its established efficacy and broad usage across various indications, particularly non-Hodgkin lymphoma (NHL).
  • Keytruda is expected to grow at the fastest CAGR of 18.9% over the forecast period, owing to its status as a leading immunotherapy option, particularly for advanced or refractory cases.
  • Hospital pharmacies dominated the market and accounted for the largest revenue share of 36.1% in 2024 attributed to the increasing prevalence of lymphoma cases requiring specialized care.
  • The lymphoma treatment market in North America dominated the global market and accounted for the largest revenue share of 49.0% in 2024, owing to the high prevalence of lymphoma cases, particularly non-Hodgkin lymphoma, which accounts for a significant portion of cancer diagnoses.
  • The Asia Pacific lymphoma treatment market is projected to grow rapidly due to rising incidence rates and increasing healthcare spending. Countries in this region are experiencing improvements in healthcare infrastructure and access to innovative treatments

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
  • Competitive Landscape: Explore the market presence of key players worldwide
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

The leading players in the Lymphoma Treatment market include:

  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Johnson & Johnson
  • Eli Lilly and Company
  • Abbott Laboratories.
  • AstraZeneca
  • Bayer AG
  • Novartis AG


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Drug
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Lymphoma Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Lymphoma Treatment Market: Drug Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
4.3. Hodgkin Lymphoma
4.3.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Non-Hodgkin Lymphoma
4.4.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Lymphoma Treatment Market: Drug Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
5.3. Rituxan/MabThera
5.3.1. Rituxan/MabThera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Revlimid
5.4.1. Revlimid Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Imbruvica
5.5.1. Imbruvica Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Adcetris
5.6.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Keytruda
5.7.1. Keytruda Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Opdivo
5.8.1. Opdivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Lymphoma Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Lymphoma Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
6.3. Hospital Pharmacy
6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacy
6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Specialty Pharmacy
6.5.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Others
6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Lymphoma Treatment Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
7.4.1. North America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Regulatory Framework
7.4.2.3. Competitive Insights
7.4.2.4. U.S. Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Regulatory Framework
7.4.3.3. Competitive Insights
7.4.3.4. Canada Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.5. Europe
7.5.1. Europe Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Regulatory Framework
7.5.2.3. Competitive Insights
7.5.2.4. UK Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Regulatory Framework
7.5.3.3. Competitive Insights
7.5.3.4. Germany Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Regulatory Framework
7.5.4.3. Competitive Insights
7.5.4.4. France Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Regulatory Framework
7.5.5.3. Competitive Insights
7.5.5.4. Italy Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Regulatory Framework
7.5.6.3. Competitive Insights
7.5.6.4. Spain Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Regulatory Framework
7.6.2.3. Competitive Insights
7.6.2.4. Japan Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Regulatory Framework
7.6.3.3. Competitive Insights
7.6.3.4. China Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Regulatory Framework
7.6.4.3. Competitive Insights
7.6.4.4. India Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.5. South Korea
7.6.5.1. Key Country Dynamics
7.6.5.2. Regulatory Framework
7.6.5.3. Competitive Insights
7.6.5.4. South Korea Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.6. Australia
7.6.6.1. Key Country Dynamics
7.6.6.2. Regulatory Framework
7.6.6.3. Competitive Insights
7.6.6.4. Australia Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Regulatory Framework
7.7.2.3. Competitive Insights
7.7.2.4. Brazil Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Regulatory Framework
7.7.3.3. Competitive Insights
7.7.3.4. Argentina Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.8. MEA
7.8.1. MEA Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Regulatory Framework
7.8.2.3. Competitive Insights
7.8.2.4. South Africa Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
7.8.3. UAE
7.8.3.1. Key Country Dynamics
7.8.3.2. Regulatory Framework
7.8.3.3. Competitive Insights
7.8.3.4. UAE Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Bristol-Myers Squibb Company
8.4.1.1. Overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Celgene Corporation
8.4.2.1. Overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Merck & Co., Inc.
8.4.3.1. Overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. F. Hoffmann-La Roche Ltd
8.4.4.1. Overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Seattle Genetics, Inc.
8.4.5.1. Overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Takeda Pharmaceutical Company Ltd
8.4.6.1. Overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Johnson & Johnson
8.4.7.1. Overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Eli Lilly and Company
8.4.8.1. Overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. AstraZeneca
8.4.9.1. Overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Novartis AG
8.4.10.1. Overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Lymphoma Treatment Market, by Region, 2018 - 2030 (USD Million)
Table 4 Global Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 5 Global Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 6 Global Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 7 North America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 8 North America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 9 North America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 10 North America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 U.S Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 12 U.S Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 13 U.S Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Canada Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 15 Canada Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 16 Canada Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Mexico Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 18 Mexico Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 19 Mexico Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 Europe Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 21 Europe Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 22 Europe Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 23 Europe Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 24 UK Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 25 UK Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 26 UK Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 27 Germany Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 28 Germany Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 29 Germany Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 30 France Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 31 France Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 32 France Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 33 Italy Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 34 Italy Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 35 Italy Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 36 Spain Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 37 Spain Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 38 Spain Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 39 Asia Pacific Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 40 Asia Pacific Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 41 Asia Pacific Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 42 Asia Pacific Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 43 Japan Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 44 Japan Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 45 Japan Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 46 China Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 47 China Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 48 China Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 49 India Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 50 India Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 51 India Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 52 Australia Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 53 Australia Lymphoma Treatment Market, by portability, 2018 - 2030 (USD Million)
Table 54 Australia Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 55 Australia Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 South Korea Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 57 South Korea Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 58 South Korea Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Latin America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 60 Latin America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 61 Latin America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 62 Latin America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 63 Brazil Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 64 Brazil Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 65 Brazil Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 66 Argentina Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 67 Argentina Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 68 Argentina Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 69 Middle East & Africa Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
Table 70 Middle East & Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 71 Middle East & Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 72 Middle East & Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 73 South Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 74 South Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 75 South Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 76 UAE Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
Table 77 UAE Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
Table 78 UAE Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Lymphoma treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Product and type outlook (USD Million)
Fig. 10 Type, drug, and distribution channel outlook
Fig. 11 Competitive landscape
Fig. 12 Lymphoma treatment market dynamics
Fig. 13 Lymphoma treatment market: Porter’s five forces analysis
Fig. 14 Lymphoma treatment market: PESTLE analysis
Fig. 15 Lymphoma treatment market: Type segment dashboard
Fig. 16 Lymphoma treatment market: Type market share analysis, 2024 & 2030
Fig. 17 Hodgkin lymphoma market, 2018 - 2030 (USD Million)
Fig. 18 Non-Hodgkin lymphoma market, 2018 - 2030 (USD Million)
Fig. 19 Lymphoma treatment market: Drug segment dashboard
Fig. 20 Lymphoma treatment market: Drug market share analysis, 2024 & 2030
Fig. 21 Adcetris market, 2018 - 2030 (USD Million)
Fig. 22 Opdivo market, 2018 - 2030 (USD Million)
Fig. 23 Rituxan/MabThera market, 2018 - 2030 (USD Million)
Fig. 24 Imbruvica market, 2018 - 2030 (USD Million)
Fig. 25 Keytruda market, 2018 - 2030 (USD Million)
Fig. 26 Revlimid market, 2018 - 2030 (USD Million)
Fig. 27 Others market, 2018 - 2030 (USD Million)
Fig. 28 Lymphoma treatment market: Distribution Channel segment dashboard
Fig. 29 Lymphoma treatment market: Distribution Channel market share analysis, 2024 & 2030
Fig. 30 Hospital pharmacy market, 2018 - 2030 (USD Million)
Fig. 31 Retail pharmacy market, 2018 - 2030 (USD Million)
Fig. 32 Specialty pharmacy market, 2018 - 2030 (USD Million)
Fig. 33 Lymphoma treatment market revenue, by region
Fig. 34 Regional marketplace: Key takeaways
Fig. 35 Regional marketplace: Key takeaways
Fig. 36 North America lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 37 U.S. country dynamics
Fig. 38 U.S. lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 39 Canada country dynamics
Fig. 40 Canada lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 41 Mexico country dynamics
Fig. 42 Mexico lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 43 Europe lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 44 UK country dynamics
Fig. 45 UK lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 46 Germany country dynamics
Fig. 47 Germany lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 48 France country dynamics
Fig. 49 France lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 50 Italy country dynamics
Fig. 51 Italy lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 52 Spain country dynamics
Fig. 53 Spain lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 54 Norway country dynamics
Fig. 55 Norway lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 56 Sweden country dynamics
Fig. 57 Sweden lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 58 Denmark country dynamics
Fig. 59 Denmark lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 60 Asia Pacific lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 61 Japan country dynamics
Fig. 62 Japan lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 63 China country dynamics
Fig. 64 China lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 65 India country dynamics
Fig. 66 India lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 67 Australia country dynamics
Fig. 68 Australia lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 69 South Korea country dynamics
Fig. 70 South Korea lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 71 Thailand country dynamics
Fig. 72 Thailand lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 73 Latin America lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 74 Brazil country dynamics
Fig. 75 Brazil lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 76 Argentina country dynamics
Fig. 77 Argentina lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 78 MEA lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 79 South Africa country dynamics
Fig. 80 South Africa lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 81 Saudi Arabia country dynamics
Fig. 82 Saudi Arabia lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 83 UAE country dynamics
Fig. 84 UAE lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 85 Kuwait Key country dynamics
Fig. 86 Kuwait lymphoma treatment market, 2018 - 2030 (USD Million)
Fig. 87 Company categorization
Fig. 88 Company market position analysis
Fig. 89 Strategic framework

Companies Mentioned

  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Johnson & Johnson
  • Eli Lilly and Company
  • Abbott Laboratories.
  • AstraZeneca
  • Bayer AG
  • Novartis AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.41 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.97 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type (Peripheral, Lymphoblastic), By Therapy (Radiotherapy, Immunotherapy, Stem Cell Transplantation), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type (Peripheral, Lymphoblastic), By Therapy (Radiotherapy, Immunotherapy, Stem Cell Transplantation), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 180 Pages
  • Global
From
Non-Hodgkin Lymphoma Treatment Market by Treatment Type, Application, End-User - Global Forecast 2025-2030 - Product Image

Non-Hodgkin Lymphoma Treatment Market by Treatment Type, Application, End-User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Hodgkin Lymphoma Treatment Market by Type, Treatment, End-User - Global Forecast 2025-2030 - Product Image

Hodgkin Lymphoma Treatment Market by Type, Treatment, End-User - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Cutaneous T-Cell-Lymphoma Market by Indication, Treatment, Product, End-User - Global Forecast 2025-2030 - Product Image

Cutaneous T-Cell-Lymphoma Market by Indication, Treatment, Product, End-User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Lymphoma Therapeutics Market by Treatment, End User - Global Forecast 2025-2030 - Product Image

Lymphoma Therapeutics Market by Treatment, End User - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.